300
Participants
Start Date
August 31, 2020
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
Iluvien 0.19 MG Drug Implant
0.19 mg Fluocinolone Acetonide Intravitreal Implant
Aflibercept
2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection
Investigative Site, Erie
Investigative Site, Warrenton
Investigative Site, Baltimore
Investigative Site, Cleveland
Investigative Site, Roanoke
Investigative Site, Columbia
Investigative Site, Marietta
Investigative Site, Sandy Springs
Investigative Site, Orlando
Investigative Site, Palm Beach Gardens
Investigative Site, Tampa
Investigative Site, Clearwater
Investigative Site, Beachwood
Investigative Site, Youngstown
Investigative Site, Cincinnati
Investigative Site, Detroit
Investigative Site, Grand Blanc
Investigative Site, Elmhurst
Investigative Site, Oak Park
Investigative Site, Lemont
Investigative Site, Springfield
Investigative Site, Independence
Investigative Site, Shawnee Mission
Investigative Site, Leawood
Investigative Site, West Monroe
Investigative Site, San Antonio
Investigative Site, Tulsa
Investigative Site, Dallas
Investigative Site, Houston
Investigative Site, The Woodlands
Investigative Site, San Antonio
Investigative Site, McAllen
Investigative Site, Colorado Springs
Investigative Site, Phoenix
Investigative Site, Tucson
Investigative Site, Beverly Hills
Investigative Site, Glendale
Investigative Site, Laguna Hills
Investigative Site, Santa Ana
Investigative Site, Bloomfield
Lead Sponsor
Alimera Sciences
INDUSTRY